Health Care Equipment & Services

Fisher & Paykel Healthcare’s modest 3‑4% decline highlights Asia‑Pacific market softness, driven by rising energy costs, high yields, and geopolitical tensions. Understand the impact on NZ equities, currency moves and investor risk for better portfo…

Fresenius SE’s 2.95% voting‑rights disclosure by U.S. investor The Capital Group reveals growing cross‑border institutional influence in German healthcare, highlighting potential governance shifts and strategic growth opportunities.

UnitedHealth Group’s 2026 proxy highlights transparent incentive plans, cost‑savings targets, and value‑based care moves, showing how the company balances governance, market shifts, and technology ROI.

Fresenius Medical Care outperforms a weak European market, showcasing resilient dialysis demand, solid cash flow, and strategic voting‑rights changes that may reshape governance and growth.

Explore how the State Street SPDR S&P ASX 50 ETF’s inclusion of Cochlear drives tech‑finance dynamics in healthcare, revealing cost‑benefit insights for providers.

Abbott Laboratories’ 25‑year dividend streak, 3% yield and diverse portfolio make it a strong buy for income‑focused investors, with robust margins and a focus on value‑based care and tech innovation.

Alcon AG’s 1.6% share rise on 15 May 2026 boosted Switzerland’s SMI & SLI, matching peers like Roche and Nestlé, signaling ongoing confidence in its eye‑care products and R&D.

Elevance Health’s latest governance, dividend hike, and share‑placement moves illustrate a conservative strategy that balances shareholder returns with tech‑driven, value‑based care expansion, positioning it for future reimbursement gains.

Siemens Healthineers pivots away from low‑margin diagnostics and oncology clinics, focusing capital on AI imaging and precision therapy to boost margins and growth.

UnitedHealth Group’s 2026 rebound shows how Medicare Advantage clarity, Optum’s growth engine and data‑driven cost control can drive a 23% share jump and set a 2028‑plus outlook.